Shares of Arcturus Therapeutics Holdings Inc. (ARCT) tanked over 20% on Wednesday morning.
ARCT is currently trading at $19.79, down $5.47 or 21.65%, on the Nasdaq, on a volume of 2.2 million shares, above average volume of 500 thousand. The stock has opened its trading at $20.15 after closing prior day's trading at $25.26. The stock has traded between $16.93 and $65.00 in the past 52 week period.
On Wednesday, the company announced that its self-amplifying COVID-19 mRNA vaccine candidate ARCT-154 has met primary efficacy endpoint in late-stage study.
The company reported 95% efficacy overall for prevention of severe COVID-19 disease including related deaths and 55% efficacy overall for preventing symptomatic COVID-19 disease.
"We are very pleased with these results, and to see ARCT-154 providing protection against symptomatic COVID-19 and almost complete protection against severe disease in a placebo-controlled vaccine efficacy study. This represents a key milestone for the Company and provides significant clinical validation of our STARR platform. We believe self-amplifying mRNA combined with our LUNAR delivery technology will create a path to better mRNA medicines," said Joseph Payne, President and CEO of Arcturus Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News